Drugs / NY-ESO-1c259-modified T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01892293 | Oct 2013 → Dec 2014 | plasma cell myeloma | Adaptimmune | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1c259-modified T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01892293 ↗ |
| Modality | Cell therapy | “autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR” NCT01892293 ↗ |